Marked Increase in Incident Gynecomastia: A 20-Year National Registry Study, 1998 to 2017.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 29 05 2020
accepted: 03 07 2020
pubmed: 6 8 2020
medline: 20 2 2021
entrez: 6 8 2020
Statut: ppublish

Résumé

Gynecomastia, the proliferation of mammary glandular tissue in the male, is a frequent but little-studied condition. Available prevalence data are based on selected patient populations or autopsy cases with their inherent bias. The objective of this work is to evaluate the age-related incidence and secular trends in gynecomastia in the general population. An observational, 20-year national registry study was conducted. This population-based study used nationwide registry data. Participants included all Danish males (age 0-80 years) with a first-time diagnosis of gynecomastia. All Danish males (age 0-80 years) were followed up for incident diagnosis of gynecomastia in the Danish National Patient Registry from 1998 to 2017 using the International Codes of Diseases, 10th revision, and the Danish Health Care Classification System. Age-specific incidence rates were estimated. The hypothesis tested in this study was formulated prior to data collection. Overall, a total 17 601 males (age 0-80 years) were registered with an incident diagnosis of gynecomastia within the 20-year study period, corresponding to 880 new cases per year and an average 20-year incidence of 3.4 per 10 000 men (age 0-80 years). The average annual incidence was 6.5/10 000 in postpubertal males age 16 to 20 years and 4.6/10 000 in males age 61 to 80 years, with a respective 5- and 11-fold overall increase in these 2 age groups over the 20-year period. The incidence of gynecomastia has dramatically increased over the last 20 years, implying that the endogenous or exogenous sex-steroid environment has changed, which is associated with other adverse health consequences in men such as an increased risk of prostate cancer, metabolic syndrome, type 2 diabetes, or cardiovascular disorders.

Identifiants

pubmed: 32754750
pii: 5868100
doi: 10.1210/clinem/dgaa440
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Trine Koch (T)

Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
The International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Elvira V Bräuner (EV)

Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
The International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Alexander S Busch (AS)

Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
The International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Martha Hickey (M)

Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia.

Anders Juul (A)

Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
The International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH